UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 9.

Hundsberger, T; Hottinger, A F; Roelcke, U; Roth, P; Migliorini, D; Dietrich, P Y; Conen, K; Pesce, G; Hermann, E; Pica, A; Gross, M W; Br├╝gge, D; Plasswilm, L; Weller, M; Putora, P M (2016). Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes. Journal of Neuro-Oncology, 126(1):175-183.

Neidert, M C; Schoor, O; Trautwein, C; Trautwein, N; Christ, L; Melms, A; Honegger, J; Rammensee, H G; Herold-Mende, C; Dietrich, P Y; Stevanovic, S (2013). Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy. Journal of Neuro-Oncology, 111(3):285-294.

Bady, P; Sciuscio, D; Diserens, A C; Bloch, J; van den Bent, M J; Marosi, C; Dietrich, P Y; Weller, M; Mariani, L; Heppner, F L; Macdonald, D R; Lacombe, D; Stupp, R; Delorenzi, M; Hegi, M E (2013). Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 126(1):159.

Renner, C; Zinzani, P L; Gressin, R; Klingbiel, D; Dietrich, P Y; Hitz, P; Bargetzi, M; Mingrone, W; Martinelli, G; Trojan, A; Bouabdallah, K; Lohri, A; Gyan, E; Biaggi, C; Cogliatti, S; Bertoni, F; Ghielmini, M; Brauchli, P; Ketterer, N (2012). A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica, 97(7):1085-1091.

Bady, P; Sciuscio, D; Diserens, A C; Bloch, J; van den Bent, M J; Marosi, C; Dietrich, P Y; Weller, M; Mariani, L; Heppner, F L; McDonald, D R; Lacombe, D; Stupp, R; Delorenzi, M; Hegi, M E (2012). MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 124(4):547-560.

Martinelli, G; Schmitz, S F H; Utiger, U; Cerny, T; Hess, U; Bassi, S; Okkinga, E; Stupp, R; Stahel, R; Heizmann, M; Vorobiof, D; Lohri, A; Dietrich, P Y; Zucca, E; Ghielmini, M (2010). Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. Journal of Clinical Oncology, 28(29):4480-4484.

Stupp, R; Hegi, M E; Neyns, B; Goldbrunner, R; Schlegel, U; Clement, P M; Grabenbauer, G G; Ochsenbein, A F; Simon, M; Dietrich, P Y; Pietsch, T; Hicking, C; Tonn, J C; Diserens, A C; Pica, A; Hermisson, M; Krueger, S; Picard, M; Weller, M (2010). Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology, 28(16):2712-2718.

Stupp, R; Hegi, M E; Neyns, B; Goldbrunner, R; Schlegel, U; Clement, P M J; Grabenbauer, G G; Ochsenbein, A F; Simon, M; Dietrich, P Y; Pietsch, T; Hicking, C; Tonn, J C; Diserens, A C; Pica, A; Hermisson, M; Krueger, S; Picard, M; Weller, M (2010). Reply to M.C. Chamberlain. Journal of Clinical Oncology, 28(33):e696-e697.

Sanchez-Politta, S; Favet, L; Kerl, K; Dietrich, P Y; Piguet, V (2008). Bortezomib-induced skin eruption. Dermatology, 216(2):156-158.

This list was generated on Fri Jul 28 03:54:11 2017 CEST.